The estimated Net Worth of Don R Kania is at least $209 Tysiąc dollars as of 25 April 2024. Don Kania owns over 569 units of Nanostring Technologies Inc stock worth over $404 and over the last 20 years he sold NSTG stock worth over $0. In addition, he makes $208,100 as Independent Director at Nanostring Technologies Inc.
Sign up
Don Kania NSTG stock SEC Form 4 insiders trading
Don has made over 8 trades of the Nanostring Technologies Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 569 units of NSTG stock worth $60 on 25 April 2024.
The largest trade he's ever made was exercising 5,520 units of Nanostring Technologies Inc stock on 15 June 2021 worth over $581. On average, Don trades about 559 units every 82 days since 2004. As of 25 April 2024 he still owns at least 3,838 units of Nanostring Technologies Inc stock.
You can see the complete history of Don Kania stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Don Kania biography
Dr. Don R. Kania Ph.D. serves as Independent Director of the Company. Dr. Kania also held various positions at Veeco Instruments Inc. He joined as chief technology officer in 1998, was named general manager in 1999, group president in 2003, president in 2004, and most recently president and chief operating officer in 2006. Prior to that he held technical and general management positions of increasing responsibility at Lawrence Livermore National Laboratory from 1993 to 1998 and Los Alamos National Laboratory from 1987 to 1991. From 1991 to 1993, he was Research Director at Crystallume, a manufacturer of thin film diamond coatings. Dr. Kania currently serves on the board of directors of Intuitive Surgical. He previously served as a board member of Aldevron LLC, the leading global supplier of plasmid DNA used in gene therapies, and of American Science and Engineering Inc., a leading manufacturer of X-ray imaging equipment. He is also on the Board of Trustees of Pacific University and the Oregon Health & Science University Foundation and he serves as an advisor to several privately held life sciences companies. He holds B.S., M.S. and Ph.D. degrees in physics and engineering from the University of Michigan. Kania’s demonstrated leadership as a chief executive officer of a public life science company qualifies him to serve as a director.
What is the salary of Don Kania?
As the Independent Director of Nanostring Technologies Inc, the total compensation of Don Kania at Nanostring Technologies Inc is $208,100. There are 12 executives at Nanostring Technologies Inc getting paid more, with R. Bradley Gray having the highest compensation of $7,288,840.
How old is Don Kania?
Don Kania is 65, he's been the Independent Director of Nanostring Technologies Inc since 2019. There are 1 older and 17 younger executives at Nanostring Technologies Inc. The oldest executive at Nanostring Technologies Inc is William Young, 75, who is the Independent Chairman of the Board.
What's Don Kania's mailing address?
Don's mailing address filed with the SEC is 1020, Kifer Road, Sunnyvale, Santa Clara County, California, 94086, United States.
Insiders trading at Nanostring Technologies Inc
Over the last 11 years, insiders at Nanostring Technologies Inc have traded over $114,083,977 worth of Nanostring Technologies Inc stock and bought 981,722 units worth $9,126,410 . The most active insiders traders include Charles P Jr Waite, Lifesciences Ii, L.P.Clarus... oraz Nicholas Galakatos. On average, Nanostring Technologies Inc executives and independent directors trade stock every 16 days with the average trade being worth of $4,371. The most recent stock trade was executed by Joseph M Beechem on 6 May 2024, trading 147,853 units of NSTG stock currently worth $15,569.
What does Nanostring Technologies Inc do?
nanostring technologies (nasdaq: nstg) is a publicly held provider of life science tools for translational research and molecular diagnostics. the company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. nanostring technologies provides life science tools for translational research and molecular diagnostic products. the company's ncounter® analysis system, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the ncounter dx analysis system. the company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, mirnas, or copy number variations, simultaneously with high sensitivity and precision. the company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and vali
What does Nanostring Technologies Inc's logo look like?
Complete history of Don Kania stock trades at Intuitive Surgical Inc, Nanostring Technologies Inc oraz Veeco Instruments Inc
Nanostring Technologies Inc executives and stock owners
Nanostring Technologies Inc executives and other stock owners filed with the SEC include:
-
R. Bradley Gray,
President, Chief Executive Officer, Director -
K. Thomas Bailey,
Chief Financial Officer -
Joseph Beechem,
Senior Vice President - Research and Development -
John Brown,
Senior Vice President - Sales and Marketing -
David Ghesquiere,
Senior Vice President - Corporate and Business Development -
R. Bradley Gray,
CEO, Pres & Director -
K. Thomas Bailey M.B.A.,
Chief Financial Officer -
Dr. Joseph M. Beechem,
Chief Scientific Officer and Sr. VP of R&D -
J. Chad Brown,
Sr. VP of Sales & Marketing -
David W. Ghesquiere,
Sr. VP of Corp. & Bus. Devel. -
William Young,
Independent Chairman of the Board -
Gregory Norden,
Independent Director -
Don Kania,
Independent Director -
Charles Waite,
Independent Director -
Elisha Finney,
Independent Director -
Kirk Malloy,
Independent Director -
Robert Hershberg,
Independent Director -
Elizabeth Schneider Ph.D.,
Sr. Global Marketing Mang. -
Dr. Philippa Webster Ph.D.,
Sr. Principal Scientist -
Dr. Mary Tedd Allen,
Sr. VP of Strategic Initiatives -
Kathryn Surace-Smith,
Sr. VP of HR & Legal Affairs and Corp. Sec. -
Douglas S. Farrell,
VP of Investor Relations & Corp. Communications -
Mark A. Winham,
Sr. VP of Operations -
Teresa M. Foy,
Director -
Nicholas Galakatos,
Director -
Lifesciences Ii, L.P.Clarus...,
-
Wayne Burns,
SVP, Operations & Admin -
James A Johnson,
Chief Financial Officer -
J. Chad Brown,
SVP, Sales & Marketing -
Mary Tedd Allen,
SVP, Operations -
Lifesciences Ii, L.P.Clarus...,
-
Barney Saunders,
SVP & GM, Life Sciences -
Venture Partners Vi Lpovp V...,
-
Fisher Jurvetson Fund Vii, ...,
-
Finny Kuruvilla,
Director -
Tina Susan Nova,
Director -
Bruce J. Seeley,
SVP & GM, Diagnostics -
J Wayne Cowens,
Chief Medical Officer -
Jennifer Scott Fonstad,
Director -
Bradford Crutchfield,
Director -
Janet George,
Director -
Dana E. Rollison,
Director -
John D. Gerace,
Chief Commercial Officer -
Jonathan Todd Garland,
Chief Commercial Officer